Table 3. Global MRI metrics at baseline and follow up.
| Control group | PD group | PD vs. Controls | ||||
|---|---|---|---|---|---|---|
| Baseline | Change after 12 months | Baseline | Change after 12 months | Baseline difference | Relative change after 12 months | |
| Global MRI Measures | Mean [95%CI] | Mean [95%CI] | Mean [95%CI] | Mean [95%CI] | Mean [95%CI] | Mean [95%CI] |
| % brain volume loss / year (SIENA) | - | -0.48 [-0.70 –-0.25], p<0.001 | - | -0.71 [-0.93 –-0.49], p = 0<0.001 | - | -0.23 [-0.52–0.05], p = 0.1 |
| GM perfusion (ml/100g/min) | 42.3 [38.9–45.8] | 0.2 [-3.1–3.5], p = 0.9 | 39.6 [36.0–43.2] | -0.8 [-4.3–2.7], p = 0.7 | -2.7 [-7.3–1.9], p = 0.2 | -1.0 [-5.8–3.8], p = 0.7 |
| DTI metrics from WM skeleton | ||||||
| FA | 0.41 [0.39–0.42] | -0.002 [-0.004–0.0005], p = 0.1 | 0.41 [0.39–0.43] | -0.0003 [-0.003–0.002], p = 0.8 | 0.0007 [-0.01–0.01], p = 0.9 | 0.002 [-0.002–0.006], p = 0.3 |
| MD (×10−3 mm2/s) | 0.87 [0.83–0.91] | 0.0026 [-0.0041–0.0093], p = 0.4 | 0.88 [0.85–0.92] | 0.00032 [-0.0066–0.0073], p = 0.9 | 0.012 [-0.0085–0.032], p = 0.2 | -0.0023 [-0.012–0.0073], p = 0.6 |
| L1 (×10−3 mm2/s) | 1.2 [1.2–1.3] | 0.00064 [-0.0079–0.0092], p = 0.9 | 1.3 [1.2–1.3] | -0.00062 [-0.0095–0.0082], p = 0.8 | 0.017 [-0.0018–0.036], p = 0.08 | -0.0012 [-0.013–0.011], p = 0.8 |
| RD (×10−3 mm2/s) | 0.68 [0.64–0.71] | 0.0036 [-0.0026–0.0097], p = 0.3 | 0.68 [0.65–0.72] | 0.00073 [-0.0057–0.0071], p = 0.8 | 0.0093 [-0.013–0.032], p = 0.4 | -0.0028 [-0.011–0.0060], p = 0.5 |
| Relative motion (mm) | 0.46 [0.43–0.49] | 0.0073 [-0.018–0.032], p = 0.6 | 0.47 [0.45–0.50] | 0.019 [-0.018–0.023], p = 0.5 | 0.015 [-0.023–0.053], p = 0.4 | 0.012 [-0.023–0.048], p = 0.5 |
GM = Grey matter, DTI = Diffusion Tensor Imaging, FA = Fractional Anisotropy, MD = Mean Diffusivity, L1 = axial diffusivity, RD = radial diffusivity, PD = Parkinson’s disease.